| Scenario; strategy | Cost, $ | QALYs | ΔCost, $ | ΔQALYs | ICER |
|---|---|---|---|---|---|
| Scenario 1 | |||||
| No screening, treat with interferon-free direct-acting antiviral if diagnosed | 69 769 | 14.0644 | - | - | - |
| Screen and treat with interferon-free direct-acting antiviral* | 69 871-69 877 | 14.0664 | 102-108 | 0.0020 | 50 490-53 938 |
| Scenario 2 | |||||
| No screening, treat with interferon-free direct-acting antiviral if diagnosed | 72 765 | 13.7281 | - | - | - |
| Screen and treat with interferon-free direct-acting antiviral* | 73 384-73 446 | 13.7478 | 619-681 | 0.0197 | 31 468-34 600 |
| Scenario 3 | |||||
| No screening, treat with interferon-free direct-acting antiviral if diagnosed | 72 506 | 14.2536 | - | - | - |
| Screen and treat with interferon-free direct-acting antiviral* | 72 767-72 789 | 14.2615-14.2616 | 261-284 | 0.0080 | 32 712-35 619 |
| Scenario 4 | |||||
| No screening, treat with interferon-free direct-acting antiviral if diagnosed | 84 610 | 12.7979 | - | - | - |
| Screen and treat with interferon-free direct-acting antiviral* | 84 914-84 938 | 12.8067 | 304-328 | 0.0088 | 34 614-37 167 |
Note: ICER = incremental cost-effectiveness ratio, QALY = quality-adjusted life-year.
*A range is given depending on which direct-acting antiviral is used for treating patients with genotype 1 infection.